Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3, parallel-group study.

Autor: de Bruyn G; Sanofi, Swiftwater, PA, USA., Wang J; Sanofi, Chengdu, China., Purvis A; Sanofi, Waltham, MA, USA., Ruiz MS; Sanofi, Paris, France., Adhikarla H; Sanofi, Swiftwater, PA, USA., Alvi S; Chicago Clinical Research Institute, IL, USA., Bonaparte MI; Sanofi, Swiftwater, PA, USA., Brune D; Optimal Research, Peoria, IL, USA., Bueso A; Demedica, San Pedro Sula, Honduras., Canter RM; Sanofi, Swiftwater, PA, USA., Ceregido MA; GSK, Wavre, Belgium., Deshmukh S; Griffith University, Australia., Diemert D; School of Medicine and Health Sciences, George Washington University, Washington, DC, USA., Finn A; Bristol Vaccine Centre, Schools of Population Health Sciences and of Cellular and Molecular Medicine, University of Bristol, Bristol, UK., Forrat R; Sanofi, Marcy l'Etoile, France., Fu B; Sanofi, Swiftwater, PA, USA., Gallais J; Sanofi, Marcy l'Etoile, France., Griffin P; Mater Health, Brisbane, Queensland, Australia.; The University of Queensland, Brisbane, Queensland, Australia., Grillet MH; Sanofi, Lyon, France., Haney O; Sanofi, Swiftwater, PA, USA., Henderson JA; Black Hills Center for American Indian Health, SD, USA., Koutsoukos M; GSK, Wavre, Belgium., Launay O; Université Paris Cité; Inserm, F-CRIN I REIVAC, Assistance Publique Hôpitaux de Paris, Hôpital Cochin, Paris, France., Torres FM; Pediatrics Department, Translational Pediatrics and Infectious Diseases Section, Santiago de Compostela, Spain.; Genetics, Vaccines- Infectious Diseases and Pediatrics Research Group GENVIP, Instituto de Investigación Sanitaria de Santiago (IDIS), Universidade de Santiago de Compostela (USC), Santiago de Compostela, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain., Masotti R; Sanofi, Swiftwater, PA, USA., Michael NL; Walter Reed Army Institute of Research, Silver Spring, MD, USA., Park J; Sanofi, Sydney, Australia., Rivera-Medina DM; INVERIME S.A, Tegucigalpa, Honduras., Romanyak N; Sanofi, Swiftwater, PA, USA., Rook C; Cmax, Adelaide, Australia., Schuerman L; GSK, Wavre, Belgium., Sher LD; Peninsula Research Associates, Rolling Hills Estates, CA, USA., Tavares-Da-Silva F; GSK, Wavre, Belgium., Whittington A; London North West University Healthcare NHS Trust, London, UK., Chicz RM; Sanofi, Waltham, MA, USA., Gurunathan S; Sanofi, Swiftwater, PA, USA., Savarino S; Sanofi, Swiftwater, PA, USA., Sridhar S; Sanofi, Reading, UK.

Publikováno v: EClinicalMedicine [EClinicalMedicine] 2023 Jul 22; Vol. 62, pp. 102109. Date of Electronic Publication: 2023 Jul 22 (Print Publication: 2023).

Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease.

Autor: Hadinegoro SR; From Cipto Mangunkusumo Hospital, University of Indonesia, Jakarta (S.R.H.); Instituto Nacional de Pediatria, Mexico City (J.L.A.-G.); Research Institute for Tropical Medicine, Muntinlupa City, the Philippines (M.R.C.); Caribbean Travel Medicine Clinic, San Juan, Puerto Rico (C.D.); Queen Sirikit National Institute of Child Health (T.C.), Faculty of Tropical Medicine, Mahidol University (K.L.), and Sanofi Pasteur (D.C.) - all in Bangkok, Thailand; Nucleo de Doencas Infecciosas, Universidade Federal do Espirito Santo, Vitoria, ES, Brazil (R.D.); Hospital Kuala Lumpur, Kuala Lumpur, Malaysia (H.I.H.M.I.); Centro de Atencion e Investigacion Medica SAS-CAIMED (H.R.), and Sanofi Pasteur (M.C.) - both in Bogota, Colombia; Organizacion para el Desarrollo y la Investigacion Salud en Honduras (ODIS), Tegucigalpa (D.M.R.-M.); Pasteur Institute in Ho Chi Minh City, Ho Chi Minh City, Vietnam (H.N.T.); Sanofi Pasteur, Singapore, Singapore (A.B., C.F., T.A.W.); Sanofi R&D, Chilly-Mazarin (K.F.), Marcy l'Etoile (R.F., E.P.), and Lyon (S.G., N.J., M.S.) - all in France; Sanofi Pasteur, Swiftwater, PA (F.N.); and Sanofi Pasteur, Montevideo, Uruguay (B.Z.)., Arredondo-García JL, Capeding MR, Deseda C, Chotpitayasunondh T, Dietze R, Muhammad Ismail HI, Reynales H, Limkittikul K, Rivera-Medina DM, Tran HN, Bouckenooghe A, Chansinghakul D, Cortés M, Fanouillere K, Forrat R, Frago C, Gailhardou S, Jackson N, Noriega F, Plennevaux E, Wartel TA, Zambrano B, Saville M

Publikováno v: The New England journal of medicine [N Engl J Med] 2015 Sep 24; Vol. 373 (13), pp. 1195-206. Date of Electronic Publication: 2015 Jul 27.

Safety and immunogenicity of a recombinant tetravalent dengue vaccine in 9-16 year olds: a randomized, controlled, phase II trial in Latin America.

Autor: Villar LÁ; From the *Centro de Investigaciones Epidemiológicas, Universidad Industrial de Santander, Bucaramanga, Colombia; †Organización para el Desarrollo y la Investigación Salud en Honduras, Tegucigalpa, Honduras; ‡Instituto Nacional de Pediatría, Unidad de Apoyo a la Investigación Clínica, Mexico City, Mexico; §Sanofi Pasteur, Swiftwater, PA; ¶Sanofi Pasteur, Montevideo, Uruguay; ‖Sanofi Pasteur, Bogota, Colombia; and **Sanofi Pasteur, Mexico City, Mexico., Rivera-Medina DM, Arredondo-García JL, Boaz M, Starr-Spires L, Thakur M, Zambrano B, Miranda MC, Rivas E, Dayan GH

Publikováno v: The Pediatric infectious disease journal [Pediatr Infect Dis J] 2013 Oct; Vol. 32 (10), pp. 1102-9.